Ablynx's (ABLYF) CEO Edwin Moses on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Feb 26, 2:19PM CST
Small companies lead the I-O class of Cancer Therapies
ACCESSWIRE - Fri Aug 08, 7:02AM CDT
Los Angeles, CA / August 8, 2014 / Tumor cells, tending to persist after treatment, lead to remission and have been a bane to cancer researchers and doctors for decades. Only recently, immuno-oncology, labeled 'I-O' first by Bristol-Myers Squibb Company (NYSE:BMY) has emerged to become a new class of cancer medicines that may someday take a meaningful place alongside chemotherapy, surgery, and radiation.
CLSN: 2.59 (+0.02), NWBO: 8.12 (+0.07), CVM: 0.84 (-0.03), CLDX: 25.81 (+0.06), INCY: 106.86 (+0.08), AZN: 69.29 (-0.81), MRK: 60.23 (+0.45), NLNK: 39.69 (+1.57), PPHM: 1.37 (+0.05), BMY: 67.64 (+0.19), FPRX: 21.11 (-0.06)
PUBLICATION IN ACCORDANCE WITH ARTICLE 15 OF THE BELGIAN LAW OF 2 MAY 2007 ON THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW"
GlobeNewswire - Thu Jul 03, 11:07AM CDT
Ablynx [Euronext Brussels: ABLX] announces that the closing of its private placement ("Accelerated Bookbuild Offering"/"ABO"